A Study to Evaluate the Respiratory Safety of TS-142 in Patients With Obstructive Sleep Apnea Hypopnea.
Latest Information Update: 29 Nov 2021
At a glance
- Drugs Vornorexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 21 Nov 2021 Status changed from recruiting to completed.
- 03 Mar 2021 Status changed from not yet recruiting to recruiting.
- 11 Feb 2021 New trial record